MIM
UBX

MetLife Investment Management’s Unity Biotechnology UBX Stock Holding History

MetLife Investment Management’s Portfolio UBX Stock Details UBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-1,468
Closed -$127K – 2333
2020
Q2 		$127K Buy
+1,468
New +$109K ﹤0.01% 2140
2019
Q3 		– Sell
-1,471
Closed -$140K – 2401
2019
Q2 		$140K Buy
+1,471
New +$125K ﹤0.01% 2227
2019
Q1 		– Sell
-1,206
Closed -$196K – 2590
2018
Q4 		$196K Buy
+1,206
New +$160K ﹤0.01% 1915

Other funds holding UBX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MC
Mayo Clinic Rochester, Minnesota $2.9M AUM 14.49% 1-Year Est. Return
IFA
Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

MetLife Investment Management's UBX Position: Q3 2020 in Review

MetLife Investment Management sold out of Unity Biotechnology (UBX) in Q3 2020, closing a stake of 1,468 shares — an estimated $127K sold.

MetLife Investment Management first reported a position in UBX in Q4 2018 and held it in 3 quarters. The position peaked at $196K in Q4 2018. 79 funds tracked by Wall St. Rank hold UBX as of Q3 2020.

  • MetLife Investment Management reported no remaining Unity Biotechnology position as of Q3 2020 after selling out during the quarter.
  • MetLife Investment Management sold 1,468 Unity Biotechnology shares in Q3 2020, an estimated $127K.
  • MetLife Investment Management first reported a position in Unity Biotechnology in Q4 2018 and held it in 3 quarters.
  • MetLife Investment Management's Unity Biotechnology position peaked at $196K in Q4 2018.
  • 79 funds tracked by Wall St. Rank held Unity Biotechnology as of Q3 2020.

Based on MetLife Investment Management's 13F filing for Q3 2020, filed 13 Nov 2020.